NEW YORK, Aug. 02, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that management will be participating in Sidoti’s Micro-Cap Virtual Conference taking place August 16-17, 2023. Management will be presenting a corporate overview on August 17 at 10:00am Eastern time and will be hosting one-on-one meetings with investors.
The presentation will be webcast live and available for replay in the Investors section of LifeMD’s website by clicking here. To register for the conference, visit www.sidoti.com/events. Registration is free and investors are not required to be a Sidoti client.
About LifeMD™
LifeMD is a direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.
Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.10 |
Daily Change: | -0.12 -2.30 |
Daily Volume: | 154,085 |
Market Cap: | US$220.880M |
November 07, 2024 November 06, 2024 October 23, 2024 September 19, 2024 August 07, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB